Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Maven Pet›
Analysis
AddedMay 15, 2026
UpdatedJul 6, 2026
Maven Pet

Maven Pet

Maven Pet develops a clinical-grade 24/7 health monitor for dogs and cats.

HQ
New York, NY, US
Founded
2021
Loading
Overview
Analysis
Compare
Fundraising
Employees
Website

Contents

  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Pricing Strategy
  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Pricing Strategy

Memo

Maven Pet has raised approximately $9 million across three funding rounds since its founding in 2021. The rounds include an initial investment in summer 2021, a $3 million seed round in 2022 led by Mustard Seed Maze and Armilar Venture Partners, and a $4.42 million round announced on September 5, 2024, led by Touro Capital Partners with participation from BlueCrow, Iberis Capital, Mustard Seed Maze, and Armilar Venture Partners.

The September 2024 round values the company as it scales operations across the United States and prepares for market entry in Portugal, building partnerships with veterinary clinics and expanding its AI-Vet platform capabilities.

Product Overview

Maven Pet's AI-Vet platform combines a lightweight collar-mounted sensor and companion mobile app to deliver continuous 24/7 health monitoring for dogs and cats. The sensor tracks activity, rest, respiratory rate, heart rate, itch behaviors, and water intake, establishing personalized baselines via machine learning and flagging meaningful deviations to pet owners and veterinarians.

The IPX7 waterproof sensor measures 1.6 x 1.1 x 0.3 inches, weighs 0.5 oz, and lasts 5-7 days per charge. The mobile app supports iOS 17+ and Android 12+, accommodates up to 3 pets per account, and integrates with clinic software for access to medical records and treatment plans. Subscription pricing is $13.99/month billed annually or $19.99/month monthly, with a 30-day return policy and 6-month minimum for monthly subscribers.

Market Outlook

Maven Pet is primarily focused on the U.S. market, where its solution is available in over 20 states including New York and California. The company is preparing to enter the Portuguese market through partnerships with clinics and specialist veterinarians in Porto, Lisbon, Braga, Cascais, Oeiras, and Gaia.

The CEO has noted organic interest from Canada, the United Kingdom, and Australia. The company operates a hybrid, flexible work model with offices in downtown Porto and currently employs approximately 17-19 people. Maven Pet has raised approximately $9 million across three funding rounds since 2021.

Pricing Strategy

Maven Pet Health Tracker is offered as a subscription service with two pricing tiers: $13.99 per month when billed annually (30% savings) or $19.99 per month on a monthly plan. The annual plan includes the sensor hardware as part of the subscription.

The service supports up to 3 pets per account. Customers benefit from a 30-day return policy, while monthly subscribers are subject to a 6-month minimum commitment. This pricing model reflects a B2C subscription approach combining hardware and software-as-a-service revenue.